1. 3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation
- Author
-
Thomas I. Davis, Carol B. Fox, Michael C. Wirtz, Michael G. Vetelino, F. David Tingley, Krista E. Bianco, Robert S. Mansbach, David W. Schulz, Jotham Wadsworth Coe, Crystal G. Bashore, Hans Rollema, Eric P. Arnold, Paige Roanne Palmer Brooks, Steven B. Sands, Brian T. O’Neill, and Lorraine A. Lebel
- Subjects
Clinical Biochemistry ,Pharmaceutical Science ,Receptors, Nicotinic ,Pharmacology ,Biochemistry ,Partial agonist ,Nicotine ,Structure-Activity Relationship ,chemistry.chemical_compound ,Piperidines ,In vivo ,Drug Discovery ,medicine ,Animals ,Varenicline ,Receptor ,Molecular Biology ,Acetylcholine receptor ,Molecular Structure ,Organic Chemistry ,Rats ,Nicotinic acetylcholine receptor ,Nicotinic agonist ,chemistry ,Cyclization ,Molecular Medicine ,Smoking Cessation ,medicine.drug - Abstract
3,5-Bicyclic aryl piperidines are a new class of high-affinity alpha4beta2 nicotinic receptor agents. We have sought nicotinic receptor partial agonists of the alpha4beta2 nicotinic acetylcholine receptor for smoking cessation, and a number of compounds fulfill potency, selectivity, and efficacy requirements in vitro. In vivo, selected agents demonstrate potent partial agonist efficacy on the mesolimbic dopamine system, a key measure of therapeutic potential for smoking cessation.
- Published
- 2005
- Full Text
- View/download PDF